Aurinia Pharmaceuticals (AUPH) Stock Overview
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AUPH Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$21
FV
27.2% undervalued intrinsic discount15.00%
Revenue growth p.a.
92
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Aurinia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.29 |
| 52 Week High | US$19.25 |
| 52 Week Low | US$10.34 |
| Beta | 1.4 |
| 1 Month Change | -4.20% |
| 3 Month Change | -1.67% |
| 1 Year Change | 25.12% |
| 3 Year Change | 60.10% |
| 5 Year Change | 6.70% |
| Change since IPO | 645.85% |
Recent News & Updates
Seeking Alpha • Aug 12
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Summary Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates. AUPH's acquisition of Kezar Life Sciences brought in a new drug, but it is not clear what AUPH plans to do with that drug. Read the full article on Seeking Alpha
Narrative Update • Jul 17
Aritinercept Advances, but Commercialization Remains a 2030s Story
Aritinercept: Development Timeline and Key Milestones Aritinercept is Aurinia Pharmaceuticals’ emerging autoimmune asset, built around a dual BAFF/APRIL inhibition mechanism intended to modulate B‑cell activity. While still early in development, the program has progressed enough that investors can begin to outline a realistic timeline toward potential market entry.Narrative Update • Jul 11
Lupus Nephritis Market Expansion: Implications for Aurinia Pharmaceuticals
The lupus nephritis (LN) market continues to evolve into one of the most important segments within autoimmune therapeutics. Rising disease prevalence, earlier diagnosis, and a shift toward targeted, steroid‑sparing treatments are reshaping expectations for companies operating in this space.New Narrative • Jul 09
Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche
Aurinia Pharmaceuticals (NASDAQ: AUPH) continues to prove that clarity can outperform complexity. With Lupkynis (voclosporin) as its single commercial asset for lupus nephritis , the company has turned concentration into discipline.Recent updates
Seeking Alpha • Aug 12
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Summary Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates. AUPH's acquisition of Kezar Life Sciences brought in a new drug, but it is not clear what AUPH plans to do with that drug. Read the full article on Seeking AlphaNarrative Update • Jul 17
Aritinercept Advances, but Commercialization Remains a 2030s Story
Aritinercept: Development Timeline and Key Milestones Aritinercept is Aurinia Pharmaceuticals’ emerging autoimmune asset, built around a dual BAFF/APRIL inhibition mechanism intended to modulate B‑cell activity. While still early in development, the program has progressed enough that investors can begin to outline a realistic timeline toward potential market entry.Narrative Update • Jul 11
Lupus Nephritis Market Expansion: Implications for Aurinia Pharmaceuticals
The lupus nephritis (LN) market continues to evolve into one of the most important segments within autoimmune therapeutics. Rising disease prevalence, earlier diagnosis, and a shift toward targeted, steroid‑sparing treatments are reshaping expectations for companies operating in this space.New Narrative • Jul 09
Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche
Aurinia Pharmaceuticals (NASDAQ: AUPH) continues to prove that clarity can outperform complexity. With Lupkynis (voclosporin) as its single commercial asset for lupus nephritis , the company has turned concentration into discipline.
Narrative Update • Jun 24
AUPH: Future Rerating Will Rely On Autoimmune Pipeline Expansion
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals unchanged at $20.85 per share, making only modest adjustments to assumptions on the discount rate, revenue growth, profit margin, and future P/E based on recent peer takeover valuations and updated Street research. What's in the News for Aurinia Pharmaceuticals Aurinia Pharmaceuticals stock rose 6.5% on higher-than-average trading volume, with investors focused on growth potential beyond lead drug Lupkynis, according to recent coverage citing a P/E of 7.24 and a sector valuation ranking of 288 out of 388 (source: Zacks / recent news reports).Analysis Article • Jun 17
Aurinia Pharmaceuticals (AUPH) Stock Could Be 4.6% Undervalued After New LUPKYNIS Phase 3 Data
Aurinia Pharmaceuticals (AUPH) is back in focus after presenting new AURORA 1 Phase 3 data at the EULAR 2026 Congress, highlighting LUPKYNIS outcomes in adults with lupus nephritis. See our latest analysis for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals stock has gained momentum recently, with a 30 day share price return of 6.15% and a 90 day share price return of 15.20%. The 1 year total shareholder return of 105.06% and 3 year total shareholder return of 69.49% point to strong longer...
Narrative Update • Jun 05
AUPH: Kidney Outcomes Data And Capital Moves Will Shape Balanced 2026 Outlook
Analysts now see Aurinia Pharmaceuticals' fair value holding steady at $17.00 per share, with a slightly lower discount rate and marginally adjusted revenue growth, profit margin, and future P/E assumptions supporting the updated target range following recent sector M&A comparisons. What's in the News LUPKYNIS data from the AURORA 1 Phase 3 study presented at the EULAR 2026 Congress show a statistically significant 53% reduction in risk of renal related events or death for lupus nephritis patients, with additional signals on death, treatment failure, and worsening proteinuria, according to the new analysis.Narrative Update • May 21
AUPH: Future Rerating Will Rely On Sector Takeout Benchmarks
Narrative Update on Aurinia Pharmaceuticals Analysts now frame Aurinia Pharmaceuticals with a slightly revised price target of about $20.85 from $21.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E after reviewing recent sector takeout valuations. Analyst Commentary Recent commentary links Aurinia Pharmaceuticals to broader sector M&A activity, with bullish analysts pointing to the Kezar Life Sciences takeover valuation as a useful reference point for what acquirers have been willing to pay for comparable assets.Analysis Article • May 15
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions
We didn't see Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) stock surge when it reported robust earnings recently. We...Narrative Update • May 05
AUPH: Sector Deal Benchmarks And 2026 Outlook Will Support Balanced Case
Analysts maintained their $17.00 price target for Aurinia Pharmaceuticals, citing updated model inputs and recent sector deal activity as supporting factors for their view of the stock’s current valuation. Analyst Commentary Bullish Takeaways Bullish analysts point to the Kezar Life Sciences takeover valuation as a helpful reference point, suggesting that recent transaction pricing in the sector supports the maintained US$17.00 target for Aurinia Pharmaceuticals.
Narrative Update • Apr 20
AUPH: Future Returns Will Depend On Execution And Disciplined Takeover Multiples
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals steady at $15.00. They cite updated modeling that slightly adjusts the discount rate, revenue growth outlook, profit margin assumptions, and forward P/E multiple in light of recent peer takeover valuations in the biotech space.Narrative Update • Apr 06
AUPH: Richer Future P/E Will Rely On Executing Post Takeover Hopes
Analysts have raised their price target on Aurinia Pharmaceuticals to $15.00 from $13.00, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E, informed in part by recent takeover valuation discussions in the sector. Analyst Commentary Analysts highlighting the recent Kezar Life Sciences takeover discussion point out that the implied valuation framework is one reference point for Aurinia Pharmaceuticals, but not a firm roadmap.Narrative Update • Mar 23
AUPH: Stable 2026 Outlook And Buyback Progress Will Support Bullish Case
Analysts have kept their $17.00 price target for Aurinia Pharmaceuticals essentially unchanged, citing stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News Aurinia issued earnings guidance for 2026, projecting total revenue in a range of $315 million to $325 million.Narrative Update • Mar 08
AUPH: Higher 2026 Outlook And Margin Assumptions Will Support Bullish Case
Analysts have nudged their fair value estimate for Aurinia Pharmaceuticals from $16.67 to $17.00, reflecting updated assumptions around a slightly lower revenue growth outlook, a modestly higher profit margin, a small adjustment to the discount rate, and a higher future P/E multiple. What's in the News Aurinia issued 2026 earnings guidance, with total revenue expected in a range of $315 million to $325 million, and net product sales projected between $305 million and $315 million, both framed relative to 2025 levels (Key Developments).Narrative Update • Feb 22
AUPH: Richer Future P/E Will Heighten Risk From Lower Profitability
Analysts have raised their fair value estimate for Aurinia Pharmaceuticals from $9.00 to $13.00 per share, citing updated assumptions that combine a higher projected revenue growth rate with a richer future P/E multiple and a lower expected profit margin profile. Valuation Changes Fair Value: increased from $9.00 to $13.00 per share, representing a sizeable uplift in the intrinsic value estimate.Narrative Update • Feb 08
AUPH: Refined Discount Rate And Margins Will Support More Constructive Outlook
Analysts have adjusted their price target for Aurinia Pharmaceuticals to US$16.67. The updated view reflects slightly higher discount rate and profit margin assumptions, along with a modest tweak to projected revenue growth and future P/E.Narrative Update • Jan 25
AUPH: Future Rerating Will Hinge On Aritinercept Development Clarity
Analysts have modestly increased their price target on Aurinia Pharmaceuticals to $15, up from $9, citing stronger than expected Lupkynis sales, improved operating leverage, and a desire for more clarity around aritinercept's development path before taking a more aggressive stance. Analyst Commentary Recent research reflects a more balanced stance on Aurinia Pharmaceuticals, even as the official price target is now set at $15, compared with the prior $9 level.Narrative Update • Jan 10
AUPH: Higher Fair Value View Will Hinge On Lupus Nephritis Franchise
Analysts have raised their price target on Aurinia Pharmaceuticals from $16.46 to $21.00, reflecting updated assumptions on growth, profitability, and future P/E. They also highlight Lupkynis performance and the recent shift to a Sector Perform rating as key context for the revised outlook.Narrative Update • Dec 17
AUPH: Legal Overhang And Pipeline Clarity Will Shape Balanced Near-Term Outlook
Analysts have nudged their fair value estimate for Aurinia Pharmaceuticals slightly higher to about $16.67 from $16.50, citing stronger than anticipated Lupkynis sales, improved operating leverage, and a more balanced risk reward profile that tempers the prior upside skew. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Lupkynis sales have materially outperformed initial expectations, reinforcing confidence in the durability of the core nephrology franchise and supporting higher revenue run rate assumptions.Narrative Update • Dec 03
AUPH: Legal Overhang And Pipeline Uncertainty Will Likely Define Near-Term Performance
Analysts have modestly increased their price target on Aurinia Pharmaceuticals to approximately $16.50 per share from around $15.00, citing stronger than expected Lupkynis sales, improved operating leverage, and a more balanced risk reward profile, while noting that some caution is still warranted until there is greater clarity on aritinercept's development path. Analyst Commentary Recent commentary reflects a more balanced stance on Aurinia Pharmaceuticals, with valuation catching up to improving fundamentals and leaving less room for multiple expansion without new catalysts.Narrative Update • Nov 19
AUPH: Risk And Opportunity Dynamics Will Likely Shape Performance Heading Into 2025
Narrative Update on Aurinia Pharmaceuticals Analysts have raised their price target for Aurinia Pharmaceuticals from $13 to $16.50 per share. They cite continued strong Lupkynis sales and improved operating leverage as key factors behind the increased valuation.Analysis Article • Nov 08
Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 27% share price jump...Narrative Update • Nov 05
AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments
Analysts have raised their fair value price target for Aurinia Pharmaceuticals from $11.71 to $13.00. They cite stronger-than-expected Lupkynis sales and improved profit margins as key factors supporting this upward revision.Analysis Article • May 19
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality
The subdued stock price reaction suggests that Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) strong earnings didn't...Analysis Article • May 15
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just released its latest quarterly results and things are looking bullish...Analysis Article • May 09
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Aurinia Pharmaceuticals to hold its Annual General Meeting on 15th of May CEO Peter Greenleaf's total...
New Narrative • Apr 28
Academic Medical Centers Will Expand Lupus Care Opportunities
Expansion into medical centers and new treatment guidelines may drive higher prescriber engagement and revenue for LUPKYNIS.Seeking Alpha • Apr 26
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
Summary AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 earnings represent an opportunity to confirm that trend. AUPH is also expected to report the first clinical data from AUR200 in Q2 '25, which might allow the opportunity for the company to one day grow beyond revenues from Lupkynis. Read the full article on Seeking AlphaAnalysis Article • Apr 01
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues
Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a buy...Analysis Article • Mar 02
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 21
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Summary AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen. Read the full article on Seeking AlphaAnalysis Article • Dec 11
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25%
Despite an already strong run, Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shares have been powering on, with a gain...Seeking Alpha • Nov 08
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Summary Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years. The actions the company is taking also look like Aurinia is preparing itself to be acquired, an event that has been rumored consistently in recent years. An updated analysis around Aurinia Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 30% share price jump...Seeking Alpha • Jul 05
Aurinia Pharmaceuticals Appears Undervalued
Summary Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs. With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment. A full investment analysis around Aurinia Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
As you might know, Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just kicked off its latest quarterly results with some...Seeking Alpha • May 02
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
Summary AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug is out-licensed. AUPH bought back 3.4M shares through April 30, at an average price of $5.37 per share. Read the full article on Seeking AlphaSeeking Alpha • Apr 18
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Summary Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential increase in US sales and from international markets paired with cost savings could make Aurinia cash flow positive by the end of the year. Future patent challenge to Lupkynis is likely, but defendable. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Summary AUPH's strategic review did not result in an acquisition of the company, nor the company acquiring an asset. AUPH has decided to buy back its own stock and focus on Lupkynis. The buyback could provide support for the stock near-term, although a return to strong sales growth would provide better support for the bull thesis. Read the full article on Seeking AlphaAnalysis Article • Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
There's been a major selloff in Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shares in the week since it released its...Shareholder Returns
| AUPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | 0.6% | 0.1% |
| 1Y | 25.1% | 37.2% | 18.9% |
Return vs Industry: AUPH underperformed the US Biotechs industry which returned 35.8% over the past year.
Return vs Market: AUPH exceeded the US Market which returned 20.1% over the past year.
Price Volatility
| AUPH volatility | |
|---|---|
| AUPH Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AUPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AUPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 128 | Kevin Tang | www.auriniapharma.com |
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc. Fundamentals Summary
| AUPH fundamental statistics | |
|---|---|
| Market cap | US$2.06b |
| Earnings (TTM) | US$314.11m |
| Revenue (TTM) | US$311.51m |
6.5x
P/E Ratio6.5x
P/S RatioIs AUPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUPH income statement (TTM) | |
|---|---|
| Revenue | US$311.51m |
| Cost of Revenue | US$68.89m |
| Gross Profit | US$242.61m |
| Other Expenses | -US$71.50m |
| Earnings | US$314.11m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 77.88% |
| Net Profit Margin | 100.84% |
| Debt/Equity Ratio | 0% |
How did AUPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 03:16 |
| End of Day Share Price | 2026/08/17 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurinia Pharmaceuticals Inc. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Dae Gon Ha | BTIG |
| Neil Maruoka | Canaccord Genuity |